03/2016
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
International Congress on Targeted Anticancer Therapies
Read More
02/2016
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement
Keystone Symposium - New Frontiers in Understanding Tumor Metabolism
Read More
02/2016
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement
Keystone Symposium - New Frontiers in Understanding Tumor Metabolism
Read More
11/2015
A First in Human Study of the First in Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640. Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity
EORTC-NCI-AACR International Conference
Read More
11/2015
Biomarker Analyses from Dose Escalation and Expansion Phases of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients
EORTC-NCI-AACR International Conference
Read More
11/2015
FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640
EORTC-NCI-AACR International Conference
Read More
07/2015
Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression
EBioMedicine
Read More
06/2015
Translational Studies of a First-in-class FASN Inhibitor, TVB-2640, Linking Preclinical Studies to Clinical Laboratory Observations in Solid Tumor Patients
AACR Special Conference: Metabolism and Cancer
Read More
06/2015
First-in-Human Investigation of the Oral First-in-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
ASCO Annual Meeting
Read More
04/2015
Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells
ACS Chemical Biology
Read More